<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115765</url>
  </required_header>
  <id_info>
    <org_study_id>20040249</org_study_id>
    <nct_id>NCT00115765</nct_id>
  </id_info>
  <brief_title>PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study</brief_title>
  <official_title>PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether treatment with the study drug, panitumumab
      given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab
      improves progression-free survival (PFS) compared to treatment Q2-week with oxaliplatin-based
      chemotherapy and bevacizumab alone. All subjects will receive Q2-week oxaliplatin- or
      irinotecan-based chemotherapy and bevacizumab. Control arm subjects will not receive
      concomitant panitumumab therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (Oxaliplatin)</measure>
    <time_frame>Overall study</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Tumor Response Through Week 12 (Irinotecan)</measure>
    <time_frame>Overall Study</time_frame>
    <description>Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Oxaliplatin)</measure>
    <time_frame>Overall study</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response Rate (Oxaliplatin)</measure>
    <time_frame>Overall study</time_frame>
    <description>Best overall response of complete or partial response within oxaliplatin stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (Oxaliplatin)</measure>
    <time_frame>Overall Study</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (Oxaliplatin)</measure>
    <time_frame>Overall study</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Irinotecan)</measure>
    <time_frame>Overall study</time_frame>
    <description>Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (Irinotecan)</measure>
    <time_frame>Overall Study</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response Rate (Irinotecan)</measure>
    <time_frame>Overall Study</time_frame>
    <description>Best overall response of complete or partial response within irinotecan stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (Irinotecan)</measure>
    <time_frame>Overall Study</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (Irinotecan)</measure>
    <time_frame>Overall Study</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1053</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin and bevacizumab without panitumumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan and bevacizumab plus panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan and bevacizumab without panitumumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxaliplatin and bevacizumab plus panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin Based Chemotherapy</intervention_name>
    <description>Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.</description>
    <arm_group_label>Oxaliplatin and bevacizumab plus panitumumab</arm_group_label>
    <arm_group_label>Oxaliplatin and bevacizumab without panitumumab</arm_group_label>
    <other_name>FOLFOX 4</other_name>
    <other_name>FOLFOX 5</other_name>
    <other_name>Modified FOLFOX 6</other_name>
    <other_name>FOLFOX 7</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.</description>
    <arm_group_label>Irinotecan and bevacizumab plus panitumumab</arm_group_label>
    <arm_group_label>Oxaliplatin and bevacizumab plus panitumumab</arm_group_label>
    <other_name>pmab</other_name>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Based Chemotherapy</intervention_name>
    <description>Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.</description>
    <arm_group_label>Irinotecan and bevacizumab plus panitumumab</arm_group_label>
    <arm_group_label>Irinotecan and bevacizumab without panitumumab</arm_group_label>
    <other_name>FOLFIRI</other_name>
    <other_name>Douillard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .</description>
    <arm_group_label>Irinotecan and bevacizumab plus panitumumab</arm_group_label>
    <arm_group_label>Irinotecan and bevacizumab without panitumumab</arm_group_label>
    <arm_group_label>Oxaliplatin and bevacizumab plus panitumumab</arm_group_label>
    <arm_group_label>Oxaliplatin and bevacizumab without panitumumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adenocarcinoma of the colon or rectum

          -  Metastatic colorectal cancer (mCRC)

          -  Measurable disease per modified response evaluation criteria in solid tumors (RECIST)
             criteria

          -  ECOG performance status of 0 or 1

          -  Available paraffin-embedded tumor tissue (from primary tumor or metastasis) or
             unstained slides of paraffin-embedded tissue

          -  If history of other primary cancer, subject will be eligible only if she or he has:

               -  Curatively resected non-melanomatous skin cancer;

               -  Curatively treated cervical carcinoma in situ;

               -  Other primary solid tumor curatively treated with no known active disease present
                  and no treatment administered for the last 5 years.

          -  Adequate hematologic data as follows:

               -  Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9 cells/L;

               -  Platelet count greater than or equal to 100 x 10^9/L;

               -  Hemoglobin greater than or equal to 9.0 g/dL. - Adequate renal function:

               -  Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN);

               -  Urinary protein dipstick of less than 2+ (if urinary dipstick 2+ or greater, then
                  excretion of less than or equal to 1000 mg of protein per day as determined by
                  24-hour urine collection).

          -  Adequate hepatic function:

               -  Alkaline phosphatase less than or equal to 3 x ULN (if liver metastases, less
                  than or equal to 5 x ULN);

               -  Aspartate aminotransferase (serum glutamic-oxaloacetic transaminase)(AST) less
                  than or equal to 3 x ULN (if liver metastases, less than or equal to 5 x ULN);

               -  Alanine aminotransferase (serum glutamic-pyruvic transaminase) (ALT) less than or
                  equal to 3 x ULN (if liver metastases, less than or equal to 5 x ULN);

               -  Bilirubin less than or equal to 2 x ULN. - Competent to comprehend, sign, and
                  date an IRB-approved informed consent form

          -  Before any study-specific procedure, the appropriate written informed consent must be
             obtained.

        Exclusion Criteria:

          -  Prior chemotherapy or biologic (i.e., antibody or vaccine) treatment for mCRC disease
             - Last dose of adjuvant or radiosensitizing chemotherapy less than 6 months before
             randomization - Radiotherapy within 14 days before randomization

          -  Elective and/or planned major surgical procedure to be performed during the course of
             this trial (surgery that arises as needed or necessary during the course of the study,
             not agreed a priori, will not make the subject ineligible)

          -  Major surgery within 28 days before randomization

          -  Central nervous system metastases

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on baseline chest X-ray or CT-scan

          -  Clinically significant ascites

          -  Preexisting bleeding diathesis or coagulopathy or the need for full-dose
             anticoagulation

          -  Any of the following within 1 year before randomization:

               -  Myocardial infarction;

               -  Unstable angina;

               -  Symptomatic congestive heart failure;

               -  Serious uncontrolled cardiac arrhythmia;

               -  Cerebrovascular accident or transient ischemic attack;

               -  Gastrointestinal ulcer or hemorrhage;

               -  Hemoptysis;

               -  Pulmonary embolism;

               -  Deep vein thrombosis, or other significant thromboembolic event.

          -  Regular use of non-steroidal anti-inflammatory agents

          -  Female subject of childbearing potential, not abstinent, and not willing to use
             contraceptives during the course of the study and for 6 months following the last dose
             of first-line treatment

          -  Female subject who is breast-feeding or who has positive serum pregnancy test 72 hours
             prior to randomization

          -  Male subject, not abstinent, and not willing to use adequate contraception upon
             enrollment into this study and for 6 months following the last dose of first-line
             treatment

          -  Subject known to be human immunodeficiency virus (HIV) positive

          -  Subject allergic to panitumumab or any components of panitumumab formulation

          -  History of any medical or psychiatric condition or laboratory abnormality that, in the
             opinion of the investigator, may increase the risks associated with study
             participation or study drug administration or may interfere with the conduct of the
             study or interpretation of study results

          -  Subject unwilling or unable to comply with study requirements

          -  Any kind of disorder that compromises the ability of the subject to give written
             informed consent and/or comply with the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.vectibix.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135. Epub 2008 Dec 29.</citation>
    <PMID>19114685</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2005</study_first_submitted>
  <study_first_submitted_qc>June 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2005</study_first_posted>
  <results_first_submitted>August 19, 2010</results_first_submitted>
  <results_first_submitted_qc>August 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2010</results_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Panitumumab Advanced Colorectal Cancer Evaluation Study (PACCE Study)</keyword>
  <keyword>Colorectal, Colon, Rectal Cancer, Metastatic Colorectal</keyword>
  <keyword>Cancer</keyword>
  <keyword>EGFr, Clinical Trial</keyword>
  <keyword>Panitumumab, ABX-EGF</keyword>
  <keyword>Immunex, Abgenix, Amgen</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 10 March 2005 through 19 October 2006.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Irinotecan and Bevacizumab Without Panitumumab</title>
          <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
        </group>
        <group group_id="P2">
          <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
          <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
        </group>
        <group group_id="P3">
          <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
          <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
        </group>
        <group group_id="P4">
          <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
          <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="413"/>
                <participants group_id="P3" count="410"/>
                <participants group_id="P4" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80">Participants who were on study at closure or died</participants>
                <participants group_id="P2" count="313">Participants who were on study at closure or died</participants>
                <participants group_id="P3" count="289">Participants who were on study at closure or died</participants>
                <participants group_id="P4" count="84">Participants who were on study at closure or died</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="121"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
          <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
        </group>
        <group group_id="B2">
          <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
          <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
        </group>
        <group group_id="B3">
          <title>Irinotecan and Bevacizumab Without Panitumumab</title>
          <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
        </group>
        <group group_id="B4">
          <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
          <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="410"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="115"/>
            <count group_id="B4" value="413"/>
            <count group_id="B5" value="1053"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="11.9"/>
                    <measurement group_id="B2" value="59.4" spread="11.7"/>
                    <measurement group_id="B3" value="57.8" spread="12.0"/>
                    <measurement group_id="B4" value="60.8" spread="11.7"/>
                    <measurement group_id="B5" value="60.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="180"/>
                    <measurement group_id="B5" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="233"/>
                    <measurement group_id="B5" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="343"/>
                    <measurement group_id="B5" value="844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Score</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Score</description>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="253"/>
                    <measurement group_id="B5" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="160"/>
                    <measurement group_id="B5" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Metastatic Organs</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="204"/>
                    <measurement group_id="B5" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="208"/>
                    <measurement group_id="B5" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Site of Disease</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="322"/>
                    <measurement group_id="B5" value="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior adjuvant chemotherapy</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="333"/>
                    <measurement group_id="B5" value="822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (Oxaliplatin)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression</description>
        <time_frame>Overall study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (Oxaliplatin)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression</description>
          <population>Intention-to-Treat</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="8.9" upper_limit="11.0"/>
                    <measurement group_id="O2" value="11.4" lower_limit="10.5" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model covariates were ECOG status, prior chemotherapy, metastatic organs, disease site, oxaliplatin dose &lt; 85 mg/m2, and oxaliplatin dose &gt; 100 mg/m2</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Oxaliplatin)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin</description>
        <time_frame>Overall study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Oxaliplatin)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin</description>
          <population>Intention-to-Treat</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="18.4" upper_limit="20.8"/>
                    <measurement group_id="O2" value="24.5" lower_limit="20.4" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model covariates were ECOG status, prior chemotherapy, metastatic organs, disease site, oxaliplatin dose &lt; 85 mg/m2, and oxaliplatin dose &gt; 100 mg/m2</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response Rate (Oxaliplatin)</title>
        <description>Best overall response of complete or partial response within oxaliplatin stratum</description>
        <time_frame>Overall study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Rate (Oxaliplatin)</title>
          <description>Best overall response of complete or partial response within oxaliplatin stratum</description>
          <population>Intention-to-Treat</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (Oxaliplatin)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum</description>
        <time_frame>Overall Study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (Oxaliplatin)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum</description>
          <population>Intention-to-Treat</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="9.5" upper_limit="11.3"/>
                    <measurement group_id="O2" value="11.4" lower_limit="10.9" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (Oxaliplatin)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum.</description>
        <time_frame>Overall study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (Oxaliplatin)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum.</description>
          <population>Intention-to-Treat</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="5.5" upper_limit="6.0"/>
                    <measurement group_id="O2" value="5.9" lower_limit="5.7" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response Through Week 12 (Irinotecan)</title>
        <description>Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum</description>
        <time_frame>Overall Study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Irinotecan and Bevacizumab Without Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Through Week 12 (Irinotecan)</title>
          <description>Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum</description>
          <population>Intention-to-Treat</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.738</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model covariates were ECOG status, prior adjuvant chemotherapy, number of metastatic organs, and primary disease site</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Irinotecan)</title>
        <description>Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm.</description>
        <time_frame>Overall study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Irinotecan and Bevacizumab Without Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Irinotecan)</title>
          <description>Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm.</description>
          <population>Intention-to-Treat</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.257</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model covariates were ECOG status, prior adjuvant chemotherapy, number of metastatic organs, and primary disease site</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (Irinotecan)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression</description>
        <time_frame>Overall Study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Irinotecan and Bevacizumab Without Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (Irinotecan)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression</description>
          <population>Intention-to-Treat</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.2" upper_limit="13.7"/>
                    <measurement group_id="O2" value="11.7" lower_limit="9.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Progression-free Survival (Wild-type KRAS)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS)</description>
        <time_frame>Overall Study</time_frame>
        <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as wild-type, who were treated with oxaliplatin</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (Wild-type KRAS)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS)</description>
          <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as wild-type, who were treated with oxaliplatin</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="8.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="11.5" lower_limit="10.6" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Progression-free Survival (Mutant KRAS)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS)</description>
        <time_frame>Overall Study</time_frame>
        <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as mutant, who were treated with oxaliplatin</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (Mutant KRAS)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS)</description>
          <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as mutant, who were treated with oxaliplatin</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="9.1" upper_limit="11.3"/>
                    <measurement group_id="O2" value="11.0" lower_limit="9.9" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Overall Survival (Wild-type KRAS)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median</description>
        <time_frame>Overall Study</time_frame>
        <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as wild-type, who were treated with oxaliplatin</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Wild-type KRAS)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median</description>
          <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as wild-type, who were treated with oxaliplatin</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Overall Survival (Mutant KRAS)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median.</description>
        <time_frame>Overall Study</time_frame>
        <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as mutant, who were treated with oxaliplatin</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin and Bevacizumab Plus Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Oxaliplatin and Bevacizumab Without Panitumumab</title>
            <description>Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Mutant KRAS)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median.</description>
          <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as mutant, who were treated with oxaliplatin</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Objective Tumor Response Rate (Wild-type KRAS)</title>
        <description>Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS)</description>
        <time_frame>Overall Study</time_frame>
        <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as wild-type, who were treated with irinotecan</population>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Irinotecan and Bevacizumab Without Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Rate (Wild-type KRAS)</title>
          <description>Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS)</description>
          <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as wild-type, who were treated with irinotecan</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Objective Tumor Response Rate (Mutant KRAS)</title>
        <description>Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS)</description>
        <time_frame>Overall Study</time_frame>
        <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as mutant, who were treated with irinotecan</population>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Irinotecan and Bevacizumab Without Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Rate (Mutant KRAS)</title>
          <description>Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS)</description>
          <population>Subset of the KRAS Efficacy Analysis Set, composed of participants from the intention-to-treat set who received at least 1 dose of first-line treatment and for whom KRAS mutation status was assessed as mutant, who were treated with irinotecan</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response Rate (Irinotecan)</title>
        <description>Best overall response of complete or partial response within irinotecan stratum</description>
        <time_frame>Overall Study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Irinotecan and Bevacizumab Without Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Rate (Irinotecan)</title>
          <description>Best overall response of complete or partial response within irinotecan stratum</description>
          <population>Intention-to-Treat</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (Irinotecan)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum</description>
        <time_frame>Overall Study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Irinotecan and Bevacizumab Without Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (Irinotecan)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum</description>
          <population>Intention-to-Treat</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="8.3" upper_limit="14.1"/>
                    <measurement group_id="O2" value="11.9" lower_limit="9.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (Irinotecan)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum</description>
        <time_frame>Overall Study</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan and Bevacizumab Plus Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6 mg/kg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Irinotecan and Bevacizumab Without Panitumumab</title>
            <description>Irinotecan-based chemotherapy and Bevacizumab Q2W alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (Irinotecan)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum</description>
          <population>Intention-to-Treat</population>
          <units>Month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="5.9" upper_limit="8.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4.8" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose through maximum of safety FU or 30 days after last dose</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panit. Plus Bevacizumab With Chemotherapy</title>
        </group>
        <group group_id="E2">
          <title>Bevacizumab With Chemotherapy</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GRANULOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SPLENIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ECTROPION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>EYELID DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>EYELID FUNCTION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>VISUAL DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ANO-RECTAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CAECITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COLONIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DUODENAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PNEUMOPERITONEUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PELVIC MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PNEUMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GALLBLADDER FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>JAUNDICE CHOLESTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ABDOMINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CATHETER SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CELLULITIS GANGRENOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CELLULITIS STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CYSTITIS KLEBSIELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>EXTRADURAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FUNGAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FUNGAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FUNGAL SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INTERTRIGO CANDIDA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MEDIASTINITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MENINGITIS CRYPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MUSCLE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PELVIC ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PERITONEAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RASH PUSTULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CARBON MONOXIDE POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>IMPLANTABLE DEFIBRILLATOR MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD AMYLASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>BLOOD MAGNESIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPERNATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SHOULDER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COLON CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COORDINATION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FAECALURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>URETHRAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>URINARY TRACT PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>VESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>FEMALE GENITAL TRACT FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>VULVAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA PHARYNX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXACERBATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PLATYPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INTERTRIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SKIN REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>TELANGIECTASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>COLECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CRYOTHERAPY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HEPATECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HEPATIC EMBOLISATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HIGH FREQUENCY ABLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LESION EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LIVER OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>AXILLARY VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="516" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="505" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="385" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="350" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="359" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="368" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ORAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="354" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="371" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>TEMPERATURE INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SHOULDER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>EXFOLIATIVE RASH</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="331" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SKIN HYPERPIGMENTATION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

